FIMM’s Group Leader Emmy Verschuren to receive funding through Academy of Finland’s new trial designed to support scientific risk-taking
The Academy of Finland has launched a new funding trial to support particularly innovative and high quality projects confirmed to involve promising risk-taking in terms of research. FIMM-EMBL Group Leader Emmy Verschuren leads one of the ten projects that obtained funding through this new call. Her project, “Modelling Lung Tumour Cell Signalling Network Sensitivities” seeks to understand how tumour initiation and growth maintenance could be mechanistically linked to predict drug sensitivity. With FIMM’s personalised cancer screening infrastructure and mouse lung cancer models the team should be well positioned to apply their findings towards drug sensitivity profiling of patient cells.